Feature | March 31, 2014

Terumo to Purchase Arterial Remodeling Technologies’ Bioresorbable Stent Technology

Terumo Corp. Arterial Remodeling Technologies Bioresorbable Coronary Stent

March 31, 2014 — Privately held Arterial Remodeling Technologies (ART) signed a structured buyout agreement with Terumo Corp. Under the agreement, ART and Terumo Corp. will collaborate in the development of a drug eluting bioresorbable scaffold or stent, intended for use in the treatment of coronary artery disease. ART Security Holders will retain full ownership of the ART bioresorbable scaffold technology for all other indications. Terumo Corp. will make staged R&D investments in ART, and ART has granted an exclusive option to Terumo Corp. to purchase ART at any time prior to the initiation of clinical trials.

ART’s advanced bioresorbable scaffold is designed to provide a transient effective scaffold that dismantles and relinquishes its primary mechanical scaffolding function after three months, which is commonly recognized by experts as the requisite length of time necessary to allow the healing process to stabilize the artery following trauma generated by angioplasty, and to avoid recoil and constrictive remodeling.

ART wishes to thank its investors: Bpifrance, Idinvest Partners, Turenne Capital Partners, Matignon Investissement & Gestion, Vesale Partners and Amundi Asset Management.

ART also wishes to thank three esteemed institutions for their invaluable support: the Cleveland Clinic; the French national research institute, CNRS, Montpellier, France; and Descartes University, Paris.

ART’s bioresborbable stent is not approved for investigational use or sale in the United States.

For more information: www.art-stent.com, www.terumomedical.com

Related Content

Medtronic, CE Mark, Resolute Onyx DES, drug-eluting stent, expanded sizes and indications
News | Stents Drug Eluting| February 02, 2016
Medtronic plc announced the recent CE Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES,...
Abbott, Absorb, BVS, FDA review, FDA panel

The Abbott Absorb BVS.

News | Cath Lab| January 20, 2016 | Dave Fornell
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel is set to review data and offer...
News | Stents Drug Eluting| January 08, 2016
In December, Stentys announced completion of patient enrollment in DESSOLVE III. The 1,400-patient randomized clinical...
Biotronik Astron stent
Technology | Stents Peripheral| December 31, 2015
December 31, 2015 - The U.S.
Sponsored Content | Videos | TCT| November 05, 2015
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 T
Sponsored Content | Videos | TCT| November 05, 2015
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies pr
Absorb II, Absorb stent, bioresorbable stents, TCT 2015
News | Stents Bioresorbable| October 30, 2015
October 30, 2015 – Two-year follow-up data from the first randomized study comparing the Absorb everolimus-eluting bi
News | Stents Bioresorbable| October 30, 2015
October 30, 2015 — Results from a clinical trial showed that that the Abbott Absorb everolimus-eluting bioresorbable
Sponsored Content | Videos | Stents Bioresorbable| October 30, 2015
Dean Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center, and a lead investigator for
News | Stents Drug Eluting| October 27, 2015
Results from the multicenter, prospective, randomized PANDA III trial indicate that the BuMA sirolimus-eluting stent (...
Overlay Init